How CBG impacts oxidative stress and inflammation in colitis-induced mice
According to a 2013 report published in the journal, Biochemical Pharmacology, CBG may help provide relief for those suffering from inflammatory bowel disease, or IBD. Previous to the study, both scientific and anecdotal evidence indicated that CBG may have potential therapeutic value in the treatment of IBD.
The researchers of the paper, Borelli et al., induced colitis in mice to model IBD in humans. They assessed inflammation levels via specific inflammatory markers, histological analysis, and immunohistochemistry analysis. They also addressed CBG’s potential to combat nitric oxide production and oxidative stress.
The results showed that CBG may help with IBD in a number of ways. First, the inflammatory markers showed that CBG had a positive effect on colitis-induced mice. Secondly, CBG, when combined with a CB2 antagonist, seemed to reduce nitric oxide production and ameliorate some oxidative stress responses such an iNOS protein expression. Third, in the intestinal epithelial walls, CBG seemed to reduce the number of reactive oxygen species (ROS) of potentially harmful macrophages.
In summary, cannabigerol seems to drop the number of ROS in colonic epithelial cells while also reducing the production of nitrites on peritoneal macrophages. In this way, CBG appears to take a two-pronged approach to have a beneficial effect on the experimental colitis presented in their mice. Under these premises of study and data, Borrelli et al. concluded that CBG could be “considered for clinical experimentation in IBD patients.”